Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
-
Published:2022-05-10
Issue:5
Volume:48
Page:173-193
-
ISSN:1346-342X
-
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
-
language:en
-
Short-container-title:Jpn. J. Pharm. Health Care Sci.
Author:
Minamishima Takuya1, Hida Hirotake1, Miyazaki Masayuki1, Kon Shunsuke1, Senzaki Koji1, Nagai Taku2, Yamada Kiyofumi1
Affiliation:
1. Department of Hospital Pharmacy, Nagoya University Hospital 2. Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University
Publisher
Japanese Society of Pharmaceutical Health Care and Sciences
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference105 articles.
1. 1）Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, Miller W, Jamal R, Letarte N, Wong P, Routy B, Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors, Oncoimmunology, 2019, 8, e1568812. doi: 10.1080/2162402X.2019.1568812. 2. 2）Patel SP, Kurzrock R, PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy, Mol Cancer Ther, 2015, 14, 847-856. 3. 3）El-Osta H, Jafri S, Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis, Immunotherapy, 2019, 11, 189-199. 4. 4）Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, 2018, 359, 91-97. 5. 5）Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 2018, 359, 97-103.
|
|